24.52
2.15%
-0.54
After Hours:
25.00
0.48
+1.96%
Corcept Therapeutics Inc stock is currently priced at $24.52, with a 24-hour trading volume of 1.69M.
It has seen a -2.15% decreased in the last 24 hours and a -4.41% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $25.08 pivot point. If it approaches the $23.78 support level, significant changes may occur.
Previous Close:
$25.06
Open:
$25.06
24h Volume:
1.69M
Market Cap:
$2.55B
Revenue:
$482.38M
Net Income/Loss:
$106.14M
P/E Ratio:
30.27
EPS:
0.81
Net Cash Flow:
$126.90M
1W Performance:
+7.54%
1M Performance:
-4.41%
6M Performance:
-4.29%
1Y Performance:
+6.15%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650-327-3270
Address
149 Commonwealth Drive, Menlo Park
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-06-23 | Upgrade | Truist | Hold → Buy |
Apr-11-23 | Initiated | SVB Securities | Market Perform |
Apr-04-23 | Initiated | Piper Sandler | Overweight |
Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
Aug-01-22 | Downgrade | Truist | Buy → Hold |
Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
Jun-27-22 | Resumed | Canaccord Genuity | Buy |
Feb-02-22 | Initiated | Canaccord Genuity | Buy |
Jan-28-22 | Initiated | Truist | Buy |
Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
Sep-24-19 | Initiated | Jefferies | Buy |
Sep-06-19 | Initiated | H.C. Wainwright | Buy |
Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
Aug-10-18 | Reiterated | Stifel | Hold |
May-31-18 | Downgrade | Stifel | Buy → Hold |
Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
Aug-31-17 | Initiated | Stifel | Buy |
Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
Apr-21-15 | Initiated | FBR Capital | Outperform |
Jan-13-14 | Downgrade | Stifel | Buy → Hold |
Aug-09-13 | Downgrade | Janney | Buy → Neutral |
Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
Benzinga
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks Investment Research
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Zacks Investment Research
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
GlobeNewswire Inc.
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Zacks Investment Research
Corcept Therapeutics Inc Stock (CORT) Financials Data
Corcept Therapeutics Inc (CORT) Revenue 2024
CORT reported a revenue (TTM) of $482.38 million for the quarter ending December 31, 2023, a +20.04% rise year-over-year.
Corcept Therapeutics Inc (CORT) Net Income 2024
CORT net income (TTM) was $106.14 million for the quarter ending December 31, 2023, a +4.66% increase year-over-year.
Corcept Therapeutics Inc (CORT) Cash Flow 2024
CORT recorded a free cash flow (TTM) of $126.90 million for the quarter ending December 31, 2023, a +5.83% increase year-over-year.
Corcept Therapeutics Inc (CORT) Earnings per Share 2024
CORT earnings per share (TTM) was $0.95 for the quarter ending December 31, 2023, a +7.95% growth year-over-year.
Corcept Therapeutics Inc Stock (CORT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Swisher Daniel N JR | Director |
May 01 '24 |
Sale |
23.09 |
2,200 |
50,798 |
0 |
MAHONEY DAVID L | Director |
Apr 10 '24 |
Option Exercise |
1.74 |
30,000 |
52,200 |
30,000 |
Lyon Joseph Douglas | See Remarks |
Apr 04 '24 |
Option Exercise |
11.35 |
5,443 |
61,778 |
12,757 |
Lyon Joseph Douglas | See Remarks |
Apr 04 '24 |
Sale |
26.00 |
5,443 |
141,524 |
7,314 |
Swisher Daniel N JR | Director |
Apr 01 '24 |
Option Exercise |
5.86 |
2,200 |
12,892 |
2,200 |
Lyon Joseph Douglas | See Remarks |
Apr 01 '24 |
Option Exercise |
11.35 |
500 |
5,675 |
7,814 |
Swisher Daniel N JR | Director |
Apr 01 '24 |
Sale |
25.30 |
2,200 |
55,660 |
0 |
Lyon Joseph Douglas | See Remarks |
Apr 01 '24 |
Sale |
26.01 |
500 |
13,004 |
7,314 |
Maduck Sean | See Remarks |
Mar 27 '24 |
Option Exercise |
3.88 |
25,953 |
100,698 |
111,175 |
Maduck Sean | See Remarks |
Mar 27 '24 |
Sale |
25.01 |
25,953 |
649,025 |
85,222 |
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Cap:
|
Volume (24h):